Marktanalyse - Dental Pain - Pipeline Review, H2 2016

Global Markets Direct
12.2016
42 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Dental Pain - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dental Pain - Pipeline Review, H2 2016, provides an overview of the Dental Pain (Central Nervous System) pipeline landscape.

A pain in the tooth is called dental pain. This can be caused by tooth decay, damaged filling, tooth fracture, etc. Symptoms of a toothache may include: tooth pain that may be sharp, throbbing, or constant. In some people, pain results only when pressure is applied to the tooth. Swelling around the tooth, fever or headache and foul-tasting drainage from the infected tooth occurs. Treatment for a toothache depends on the cause.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dental Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dental Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dental Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dental Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 1 and 1 respectively.Dental Pain.

Dental Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dental Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dental Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dental Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dental Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dental Pain (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dental Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dental Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Dental Pain Overview 6

Therapeutics Development 7

Pipeline Products for Dental Pain - Overview 7

Dental Pain - Therapeutics under Development by Companies 8

Dental Pain - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Dental Pain - Products under Development by Companies 12

Dental Pain - Companies Involved in Therapeutics Development 13

Boehringer Ingelheim GmbH 13

Laboratorios Del Dr Esteve SA 14

Pacira Pharmaceuticals Inc 15

Teva Pharmaceutical Industries Ltd 16

Dental Pain - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Combination Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

(celecoxib + tramadol hydrochloride) - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

A-100 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

AFAP-3 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

BI-1026706 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

bupivacaine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

funapide - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Dental Pain - Dormant Projects 36

Dental Pain - Discontinued Products 38

Dental Pain - Product Development Milestones 39

Featured News & Press Releases 39

Jun 21, 2012: Iroko Pharma Announces Phase III Study Results Of Diclofenac 39

Nov 04, 2011: Phase II Results For Nano-formulated NSAIDs Under Development At Iroko Pharmaceuticals To Be Reported At ACR Meeting 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42





List of Tables

Number of Products under Development for Dental Pain, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Dental Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2016 13

Dental Pain - Pipeline by Laboratorios Del Dr Esteve SA, H2 2016 14

Dental Pain - Pipeline by Pacira Pharmaceuticals Inc, H2 2016 15

Dental Pain - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Assessment by Combination Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Dental Pain - Dormant Projects, H2 2016 36

Dental Pain - Dormant Projects (Contd..1), H2 2016 37

Dental Pain - Discontinued Products, H2 2016 38





List of Figures

Number of Products under Development for Dental Pain, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Top 10 Targets, H2 2016 19

Number of Products by Stage and Top 10 Targets, H2 2016 19

Number of Products by Top 10 Mechanism of Actions, H2 2016 21

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 25

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus